American Journal of Gastroenterology最新文献

筛选
英文 中文
Guidelines in Practice: Diagnosis and Management of Eosinophilic Esophagitis. 实践指南:嗜酸性粒细胞性食管炎的诊断和治疗。
IF 7.6 1区 医学
American Journal of Gastroenterology Pub Date : 2025-10-01 Epub Date: 2025-02-28 DOI: 10.14309/ajg.0000000000003386
Evan S Dellon
{"title":"Guidelines in Practice: Diagnosis and Management of Eosinophilic Esophagitis.","authors":"Evan S Dellon","doi":"10.14309/ajg.0000000000003386","DOIUrl":"10.14309/ajg.0000000000003386","url":null,"abstract":"","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":" ","pages":"2223-2225"},"PeriodicalIF":7.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143522486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk of Extrahepatic Malignancies in Patients With Autoimmune Hepatitis: A Nationwide Cohort Study. 自身免疫性肝炎患者肝外恶性肿瘤的风险:一项全国性队列研究
IF 7.6 1区 医学
American Journal of Gastroenterology Pub Date : 2025-10-01 Epub Date: 2024-12-24 DOI: 10.14309/ajg.0000000000003261
Sung Won Chung, Ye-Jee Kim, Jihye Lim, Jonggi Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Sehee Kim, Won-Mook Choi
{"title":"Risk of Extrahepatic Malignancies in Patients With Autoimmune Hepatitis: A Nationwide Cohort Study.","authors":"Sung Won Chung, Ye-Jee Kim, Jihye Lim, Jonggi Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Sehee Kim, Won-Mook Choi","doi":"10.14309/ajg.0000000000003261","DOIUrl":"10.14309/ajg.0000000000003261","url":null,"abstract":"<p><strong>Introduction: </strong>Nationwide, population-based data on the risk of extrahepatic malignancy in patients with autoimmune hepatitis (AIH) in Asian countries are scarce. This study aimed to examine the risk of developing extrahepatic malignancies in a nationwide cohort of patients with AIH.</p><p><strong>Methods: </strong>Using claims data from the Korean National Health Insurance Service database, patients diagnosed with AIH between 2007 and 2019 (n = 7,382) were matched in a 1:8 ratio with an age- and sex-matched control population (n = 58,320). We compared the incidence rates and hazard ratios (HRs) of overall and specific extrahepatic malignancies between the 2 groups, while also examining the impact of immunosuppressant use.</p><p><strong>Results: </strong>During a median follow-up period of 5.2 years, a total of 3,713 extrahepatic malignancies developed. The incidence rate of extrahepatic malignancy in patients with AIH (990.8 cases per 100,000 person-years) was comparable with that in the matched controls (937.6 cases per 100,000 person-years), with an HR of 0.93 (95% confidence interval (CI), 0.81-1.07; P = 0.30). However, a significantly higher risk of hematologic malignancies, particularly lymphoma or myeloma (HR, 2.66; 95% CI, 1.70-4.17; P < 0.001), was observed. The use of glucocorticoids (HR, 0.74; 95% CI, 0.31-1.75; P = 0.50) or azathioprine (HR, 2.12; 95% CI, 0.90-5.02; P = 0.09) had no impact on the risk of lymphoma or myeloma in patients with AIH.</p><p><strong>Discussion: </strong>In this nationwide, population-based cohort, AIH was not associated with an increased risk of overall extrahepatic malignancy compared with age- and sex-matched controls. However, AIH itself increased the risk of lymphoma or myeloma, independent of immunosuppressant use.</p>","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":" ","pages":"2302-2311"},"PeriodicalIF":7.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142881059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Study of the Corticoanorectal Neurophysiology in Women With Fecal Incontinence. 女性大便失禁的皮质-肛肠神经生理学研究。
IF 7.6 1区 医学
American Journal of Gastroenterology Pub Date : 2025-10-01 Epub Date: 2025-01-10 DOI: 10.14309/ajg.0000000000003295
Lluís Mundet, Tennekoon Buddhika Karunaratne, Omar Ortega, Alba Raventós, Pere Clavé
{"title":"Study of the Corticoanorectal Neurophysiology in Women With Fecal Incontinence.","authors":"Lluís Mundet, Tennekoon Buddhika Karunaratne, Omar Ortega, Alba Raventós, Pere Clavé","doi":"10.14309/ajg.0000000000003295","DOIUrl":"10.14309/ajg.0000000000003295","url":null,"abstract":"<p><strong>Introduction: </strong>Fecal incontinence (FI) is a prevalent condition that disproportionately affects women. Although sphincter biomechanics are well studied, the integrity of the corticoanal motor pathway remains elusive. We evaluated the corticospinoanorectal pathway in women with FI against age-matched (AM-HV) and young healthy (Y-HV) volunteers.</p><p><strong>Methods: </strong>Observational study with 18 women with FI (mean age: 63.4 ± 11.1), 15 AM-HV (60.7 ± 9.01), and 15 Y-HV (24.2 ± 5.39) conducted in a tertiary hospital. Patients underwent clinical evaluation, high-resolution anorectal manometry, endoanal ultrasound, and transcranial/translumbosacral magnetic stimulation to assess anorectal motor-evoked potentials (MEP). Clinical severity was measured with St. Mark score and quality of life with Fecal Incontinence Quality of Life and EQ5D.</p><p><strong>Results: </strong>Patients had longer MEP latencies than AM-HV in the cortico-anal (25.93 ± 3.67 ms vs 22.89 ± 1.38 ms) and right lumbo-rectal segments (5.64 ± 1.35 ms vs 4.39 ± 1.27 ms; P < 0.05), but not in the tibial segment (control) (33.35 ± 2.88 ms vs 32.08 ± 2.05 ms; P > 0.05). However, tibial latencies were longer in AM-HV compared with Y-HV (32.08 ± 2.05 ms vs 29.21 ± 2.75 ms; P = 0.003). In FI, 41.1% had corticoanorectal impairments, 50% lumboanal, and 44.4% sacral. Overall, 82.4% showed delayed latencies in at least one of the 12 segments. High-resolution anorectal manometry revealed 83.24% had external anal sphincter dysfunction, 40% internal sphincter dysfunction, and 23.57% both. MEP latencies inversely correlated with external anal sphincter squeeze strength. FI patients had significantly poorer EQ5D scores compared with both control groups.</p><p><strong>Discussion: </strong>Women with FI show significant neuropathy in the corticospinoanorectal pathway linked to impaired anorectal function. These findings underscore the brain-gut axis's role in FI pathophysiology, advocating for advanced neurophysiological diagnostics and targeted interventions.</p>","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":" ","pages":"2382-2391"},"PeriodicalIF":7.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142942723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Accuracy of Visual Estimation for Measuring Colonic Polyp Size: A Systematic Review and Meta-Analysis. 目测测量结肠息肉大小的准确性:系统回顾与元分析
IF 7.6 1区 医学
American Journal of Gastroenterology Pub Date : 2025-10-01 Epub Date: 2025-02-28 DOI: 10.14309/ajg.0000000000003391
Abraham Z Cheloff, Leah Kim, Mark B Pochapin, Aasma Shaukat, Violeta Popov
{"title":"Accuracy of Visual Estimation for Measuring Colonic Polyp Size: A Systematic Review and Meta-Analysis.","authors":"Abraham Z Cheloff, Leah Kim, Mark B Pochapin, Aasma Shaukat, Violeta Popov","doi":"10.14309/ajg.0000000000003391","DOIUrl":"10.14309/ajg.0000000000003391","url":null,"abstract":"<p><strong>Introduction: </strong>Measurement of colorectal polyps is typically performed through visual estimation, which is prone to bias. Studies have evaluated the accuracy of visual estimation and utility of assistive tools, but results have been mixed. The aim of this study was to clarify the accuracy of visual estimation as a measurement tool and the benefits of artificial intelligence.</p><p><strong>Methods: </strong>MEDLINE and Embase were searched through October 2024. Extraction and quality assessment were performed independently by 2 authors. The primary outcome was the pooled absolute mean difference in size between visual estimation and control. Secondary outcomes included subgroup analysis of expert vs trainee status, accuracy of artificial intelligence, study origin (East vs West), comparator type, definition of accuracy, polyp size, direction of estimation, and image type.</p><p><strong>Results: </strong>Thirty-five studies with 42,964 polyp measurements were included in our analysis. All studies were of high quality, and there was no evidence of publication bias. The pooled absolute mean difference from comparator was 1.68 mm (confidence interval 1.21-2.15) with high variability explained by differences in the comparator, direction of estimation, image type, and size of the polyp. Overall accuracy was 60% with high variability as well, with increased accuracy with video displayed over photographs. Artificial intelligence improved accuracy with an odds ratio of 7.46.</p><p><strong>Discussion: </strong>Visual estimation is an inaccurate and imprecise way to measure colorectal polyps. Further research is needed to determine the impact on clinical outcomes related to colorectal cancer. Investment in new technology to aid in polyp measurement is an important next step.</p>","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":" ","pages":"2251-2259"},"PeriodicalIF":7.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143522444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Accurately Predicting Recurrent Primary Sclerosing Cholangitis After Liver Transplantation. 准确预测肝移植后复发的原发性硬化性胆管炎
IF 7.6 1区 医学
American Journal of Gastroenterology Pub Date : 2025-10-01 Epub Date: 2025-04-07 DOI: 10.14309/ajg.0000000000003423
Ming Gao, Xuefeng Ma
{"title":"Accurately Predicting Recurrent Primary Sclerosing Cholangitis After Liver Transplantation.","authors":"Ming Gao, Xuefeng Ma","doi":"10.14309/ajg.0000000000003423","DOIUrl":"10.14309/ajg.0000000000003423","url":null,"abstract":"","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":" ","pages":"2462"},"PeriodicalIF":7.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Rare Tumor of the Esophagus: Primary Malignant Melanoma. 一罕见的食道肿瘤:原发性恶性黑色素瘤。
IF 7.6 1区 医学
American Journal of Gastroenterology Pub Date : 2025-10-01 Epub Date: 2025-03-12 DOI: 10.14309/ajg.0000000000003403
Ali Bilal Ulas, Alimurat Adiguzel, Yener Aydin, Atilla Eroglu, Ebru Sener
{"title":"A Rare Tumor of the Esophagus: Primary Malignant Melanoma.","authors":"Ali Bilal Ulas, Alimurat Adiguzel, Yener Aydin, Atilla Eroglu, Ebru Sener","doi":"10.14309/ajg.0000000000003403","DOIUrl":"10.14309/ajg.0000000000003403","url":null,"abstract":"","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":" ","pages":"2231"},"PeriodicalIF":7.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143603418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Response to Lai and Liao. 对赖和廖的回应。
IF 7.6 1区 医学
American Journal of Gastroenterology Pub Date : 2025-10-01 Epub Date: 2025-04-30 DOI: 10.14309/ajg.0000000000003444
Andrew D Mosholder, Kira Leishear
{"title":"Response to Lai and Liao.","authors":"Andrew D Mosholder, Kira Leishear","doi":"10.14309/ajg.0000000000003444","DOIUrl":"10.14309/ajg.0000000000003444","url":null,"abstract":"","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":" ","pages":"2457-2458"},"PeriodicalIF":7.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143963501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of Prior Biologic Exposure on Ozanimod Efficacy and Safety in the Phase 3 True North Clinical Trial. 在3期真北临床试验中,先前生物暴露对Ozanimod疗效和安全性的影响。
IF 7.6 1区 医学
American Journal of Gastroenterology Pub Date : 2025-10-01 Epub Date: 2025-01-08 DOI: 10.14309/ajg.0000000000003310
Bruce E Sands, David T Rubin, Edward V Loftus, Douglas C Wolf, Remo Panaccione, Jean-Frederic Colombel, Axel Dignass, Miguel Regueiro, Severine Vermeire, Anita Afzali, Garrett Lawlor, Harris A Ahmad, Hsiuanlin Wu, Mark T Osterman, Anjali Jain, Geert D'Haens
{"title":"Impact of Prior Biologic Exposure on Ozanimod Efficacy and Safety in the Phase 3 True North Clinical Trial.","authors":"Bruce E Sands, David T Rubin, Edward V Loftus, Douglas C Wolf, Remo Panaccione, Jean-Frederic Colombel, Axel Dignass, Miguel Regueiro, Severine Vermeire, Anita Afzali, Garrett Lawlor, Harris A Ahmad, Hsiuanlin Wu, Mark T Osterman, Anjali Jain, Geert D'Haens","doi":"10.14309/ajg.0000000000003310","DOIUrl":"10.14309/ajg.0000000000003310","url":null,"abstract":"<p><strong>Introduction: </strong>Patients with ulcerative colitis (UC) and prior biologic failure may have reduced or delayed efficacy with subsequent advanced therapies. This analysis evaluated the efficacy and safety of ozanimod during the True North (TN) study and its open-label extension (OLE) in biologic-exposed patients with UC.</p><p><strong>Methods: </strong>TN was a randomized, placebo-controlled 52-week trial (10-week induction, 42-week maintenance period). Eligible patients could enter the OLE. Clinical outcomes were assessed at TN week (W) 10 and W52 and OLE W46 and W94. Symptomatic efficacy was evaluated through induction and in the OLE until W94. Safety was assessed.</p><p><strong>Results: </strong>This analysis included 376 biologic-exposed patients. In the placebo-controlled cohort, more ozanimod-treated patients achieved clinical response than placebo at W10 regardless of the number or type of prior biologics; patients who used 1 vs ≥2 prior biologics achieved higher efficacy rates. Efficacy rates were higher at W52 than W10 and were similar across subgroups regardless of the number or type of prior biologics. Significantly greater proportions of ozanimod vs placebo patients achieved symptomatic response by W5 ( P = 0.0173) and symptomatic remission by W10 ( P = 0.0207). Among biologic-exposed TN W10 ozanimod nonresponders who entered the OLE, 61% achieved symptomatic response with an extra 10 weeks of ozanimod treatment. Ozanimod efficacy was durable for ∼3 years of continuous treatment in biologic-exposed W52 clinical responders who entered the OLE. No new safety signals were observed.</p><p><strong>Discussion: </strong>Ozanimod was effective and safe in biologic-exposed patients with UC, but these patients may require more time to respond to treatment. Clinical trial registry website and trial numbers: ClinicalTrials.gov , numbers NCT02435992 and NCT02531126.</p>","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":" ","pages":"2339-2349"},"PeriodicalIF":7.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12487659/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142942719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rebound in Fecal Testing, Colonoscopy Utilization, and Colorectal Neoplasia Detection During the COVID-19 Pandemic. COVID-19大流行期间粪便检测、结肠镜检查使用和结直肠肿瘤检测的反弹
IF 7.6 1区 医学
American Journal of Gastroenterology Pub Date : 2025-10-01 Epub Date: 2025-01-06 DOI: 10.14309/ajg.0000000000003293
Michael J Langevin, Christopher D Jensen, Amy R Marks, Sophie A Merchant, Jessica Badalov, Jeffrey K Lee, Angela Y Lam, Ethan A Halm, Theodore R Levin
{"title":"Rebound in Fecal Testing, Colonoscopy Utilization, and Colorectal Neoplasia Detection During the COVID-19 Pandemic.","authors":"Michael J Langevin, Christopher D Jensen, Amy R Marks, Sophie A Merchant, Jessica Badalov, Jeffrey K Lee, Angela Y Lam, Ethan A Halm, Theodore R Levin","doi":"10.14309/ajg.0000000000003293","DOIUrl":"10.14309/ajg.0000000000003293","url":null,"abstract":"<p><strong>Introduction: </strong>The COVID-19 pandemic reduced colorectal cancer (CRC) screening, but the rebound in testing and outcomes after the pandemic has not been widely reported. We evaluated CRC test utilization and colorectal neoplasia detection among screening eligible patients in a large health system in 2020 and 2021, compared with 2019 (prepandemic).</p><p><strong>Methods: </strong>Using a retrospective cohort study design, fecal immunochemical test (FIT) and colonoscopy utilization, FIT positivity, and neoplasia detection were evaluated annually in 2019-2021 among Kaiser Permanente Northern California patients aged 50-75 years overall and by sex, age, race and ethnicity, and spoken language preference.</p><p><strong>Results: </strong>Compared with 2019, reductions in FIT, colonoscopy, FIT positivity, and neoplasia detection in 2020 were followed by a strong rebound in 2021 and no subgroups by age and sex or minority subgroups by race and ethnicity or spoken language preference demonstrably lagged in their recovery in 2021. Among White persons and those with an English language preference, there was a small lag in recovery to baseline levels. The overall decline in CRC testing by colonoscopy in 2020 was offset by a lesser decrease in FIT utilization in 2020, and a strong rebound in FIT utilization in 2021 helped to offset the small lag in the rebound in colonoscopies completed in 2021.</p><p><strong>Discussion: </strong>Findings may help guide organizations looking to improve CRC screening and minimize health care disparities related to national emergencies such as pandemics. Long-term studies are needed to evaluate how pandemic-related changes in CRC screening practices will affect future CRC outcomes.</p>","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":" ","pages":"2422-2431"},"PeriodicalIF":7.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12228842/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142930517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Suggestions to Strengthen a Systematic Review. 加强系统检讨的建议。
IF 7.6 1区 医学
American Journal of Gastroenterology Pub Date : 2025-10-01 Epub Date: 2025-04-07 DOI: 10.14309/ajg.0000000000003387
Nosaibah Razaqi, Rachana Mehta, Shubham Kumar, Ranjana Sah
{"title":"Suggestions to Strengthen a Systematic Review.","authors":"Nosaibah Razaqi, Rachana Mehta, Shubham Kumar, Ranjana Sah","doi":"10.14309/ajg.0000000000003387","DOIUrl":"10.14309/ajg.0000000000003387","url":null,"abstract":"","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":" ","pages":"2458-2459"},"PeriodicalIF":7.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信